Starpharma Holdings Ltd Total Assets
Starpharma Holdings Ltd total assets. Based on the latest financial reports, Starpharma Holdings Ltd (SPL) holds total assets worth AU$19.02 Million AUD (≈ $13.46 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see SPL market cap for the company's overall valuation and market capitalisation.
Total Assets of Starpharma Holdings Ltd (2000–2026)
Total assets of Starpharma Holdings Ltd from 2000 to 2026. This chart illustrates how Starpharma Holdings Ltd's total assets have evolved over time, based on quarterly financial data. See Starpharma Holdings Ltd share price for real-time trading data and today's change.
Starpharma Holdings Ltd - Asset Composition Analysis
Starpharma Holdings Ltd Total Assets Breakdown (June 2026)
Starpharma Holdings Ltd total assets breakdown as of June 2026. Starpharma Holdings Ltd's total assets of AU$19.02 Million consist of 92.4% current assets and 7.6% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 57.9% |
| Accounts Receivable | AU$4.39 Million | 23.1% |
| Inventory | AU$1.66 Million | 8.7% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2000–2026)
This chart illustrates how Starpharma Holdings Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Starpharma Holdings Ltd's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Starpharma Holdings Ltd's current assets represent 92.4% of total assets in 2026, a decrease from 99.6% in 2000.
- Cash Position: Cash and equivalents constituted 57.9% of total assets in 2026, down from 96.7% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 23.1% of total assets.
Starpharma Holdings Ltd Competitors by Total Assets
Key competitors of Starpharma Holdings Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Starpharma Holdings Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.40 | 4.32 | 6.78 |
| Quick Ratio | 3.08 | 3.95 | 6.62 |
| Cash Ratio | 0.00 | 2.95 | 5.80 |
| Working Capital | AU$12.41 Million | AU$17.33 Million | AU$60.33 Million |
Starpharma Holdings Ltd - Advanced Valuation Insights
This section examines the relationship between Starpharma Holdings Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 24.41 |
| Latest Market Cap to Assets Ratio | 7.90 |
| Asset Growth Rate (YoY) | -25.2% |
| Total Assets | AU$19.02 Million |
| Market Capitalization | $150.21 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Starpharma Holdings Ltd's assets at a significant premium (7.90x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Starpharma Holdings Ltd's assets decreased by 25.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Starpharma Holdings Ltd (2000–2026)
The table below shows the annual total assets of Starpharma Holdings Ltd from 2000 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | AU$19.02 Million ≈ $13.46 Million |
-25.19% |
| 2025-06-30 | AU$25.42 Million ≈ $17.99 Million |
-30.95% |
| 2024-06-30 | AU$36.81 Million ≈ $26.05 Million |
-29.32% |
| 2023-06-30 | AU$52.09 Million ≈ $36.85 Million |
-21.29% |
| 2022-06-30 | AU$66.17 Million ≈ $46.82 Million |
-9.64% |
| 2021-06-30 | AU$73.24 Million ≈ $51.82 Million |
+87.41% |
| 2020-06-30 | AU$39.08 Million ≈ $27.65 Million |
-20.02% |
| 2019-06-30 | AU$48.86 Million ≈ $34.57 Million |
-16.50% |
| 2018-06-30 | AU$58.51 Million ≈ $41.40 Million |
-12.13% |
| 2017-06-30 | AU$66.59 Million ≈ $47.12 Million |
+12.79% |
| 2016-06-30 | AU$59.04 Million ≈ $41.77 Million |
+33.02% |
| 2015-06-30 | AU$44.38 Million ≈ $31.40 Million |
+20.40% |
| 2014-06-30 | AU$36.86 Million ≈ $26.08 Million |
-24.07% |
| 2013-06-30 | AU$48.55 Million ≈ $34.35 Million |
-10.54% |
| 2012-06-30 | AU$54.27 Million ≈ $38.40 Million |
+82.06% |
| 2011-06-30 | AU$29.81 Million ≈ $21.09 Million |
-20.66% |
| 2010-06-30 | AU$37.57 Million ≈ $26.58 Million |
+30.23% |
| 2009-06-30 | AU$28.85 Million ≈ $20.41 Million |
+17.01% |
| 2008-06-30 | AU$24.65 Million ≈ $17.44 Million |
-18.97% |
| 2007-06-30 | AU$30.42 Million ≈ $21.53 Million |
+21.63% |
| 2006-06-30 | AU$25.01 Million ≈ $17.70 Million |
+100.11% |
| 2005-06-30 | AU$12.50 Million ≈ $8.84 Million |
-32.40% |
| 2004-06-30 | AU$18.49 Million ≈ $13.08 Million |
+72.56% |
| 2003-06-30 | AU$10.72 Million ≈ $7.58 Million |
-43.18% |
| 2002-06-30 | AU$18.86 Million ≈ $13.34 Million |
-27.53% |
| 2001-06-30 | AU$26.03 Million ≈ $18.41 Million |
-10.42% |
| 2000-06-30 | AU$29.05 Million ≈ $20.56 Million |
-- |
About Starpharma Holdings Ltd
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRA… Read more